NMDA-blocking pharmaceuticals
Patent 5521215 Issued on May 28, 1996. Estimated Expiration Date: 
February 7, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
February 7, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesHexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents Novel tetrahydrocannabinol type compounds Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents (3S-4S)-7-hydroxy-Ɗ6 -tetrahydrocannabinols Patent #: 4876276 InventorsAssigneeApplicationNo. 192886 filed on 02/07/1994US Classes:514/454Tricyclo ring system having the hetero ring as one of the cyclosExaminersPrimary: Chan, NickyAttorney, Agent or FirmForeign Patent References
International ClassA61K 031/35Foreign Application Priority Data1989-11-07 ILAbstractPharmaceutical compositions are described for preventing neurotoxicity, crising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of Ɗ6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain chronic degenerative diseases characterized by gradual neuronal loss.Other References
| |
